REG - ReNeuron Group plc - Directorate Change

ReNeuronAnnouncement

03/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230103:nRSC4045La&default-theme=true

RNS Number : 4045L  ReNeuron Group plc  03 January 2023

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET
ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Directorate Change

Iain Ross appointed as Executive Chairman, CEO steps down

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell-derived
exosome technologies, announces that Catherine Isted, ACMA, Chief Executive
Officer ("CEO") has stepped down from her role with immediate effect.

 

Iain Ross, who has been on the Board since July 2021, has been appointed as
Executive Chairman and will lead a restructuring of the business, with further
announcements to be made in due course.

 

On behalf of the ReNeuron Board of Directors, Barbara Staehelin, Senior
Independent Director, commented: "We would like to thank Catherine for her
contribution over the past 17 months, initially as CFO and more recently as
CEO, and wish her well in the future. We are excited about the future of the
Company and are very grateful to Iain for agreeing to lead the Company going
forward. He is an experienced industry executive who has led several
successful biotech turnarounds, including more recently that of Redx Pharma
plc and Silence Therapeutics plc."

 

ENDS

 

Contacts:

 

 ReNeuron                                          www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Executive Chairman                     Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Liberum Capital Limited (NOMAD and Joint Broker)                                    +44 (0)20 3110 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)            +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)          +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                   (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings                     +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Company has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-licence both these programmes in other territories.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABUGDBUBGDGXD